South Korea’s medical AI industry faces a critical gap between technical achievement and commercial viability, according to industry leaders at the MSD Innovation Summit. While the country possesses digital infrastructure and medical data, experts state that a lack of clear payment models and business strategies prevents these innovations from scaling into sustainable businesses.
South Korea is well-positioned to lead AI-driven healthcare due to its high level of digitalization and a robust startup ecosystem, according to Kim Kyung-hoon, representative of OpenAI Korea. However, the ability to develop a high-performing model does not automatically translate into market growth.
Hwang Hee, representative of Kakao Healthcare, identified a fundamental “payer gap” as a primary obstacle. In digital health, the person using the service—such as a doctor or patient—is often not the person paying for it. Hwang noted that while the user is usually clear, the entity responsible for the cost remains ambiguous, which stifles adoption. To overcome this, companies must provide quantitative evidence of cost reduction and improved clinical outcomes to convince payers of the technology’s value.
Strategic Shifts in Government and Regulatory Support
Governmental support is currently viewed as lagging behind the pace of industrial innovation.
Hwang Hee argued that the government must move away from traditional “System Integration” (SI) project models, which treat digital health as a simple IT procurement task. Instead, he urged the state to focus on creating the rules and environments that allow companies to grow independently. He emphasized that AI integration requires a broader social consensus on evaluation systems and the roles of various stakeholders.
Global Partnerships as a Catalyst for Scaling
Global pharmaceutical companies are increasingly viewing themselves as ecosystem orchestrators rather than just drug manufacturers. Albert Kim, representative of MSD Korea, stated that MSD is expanding its focus to include prevention, diagnosis, and digital solutions.
According to Kim, global firms can bridge the gap for Korean startups by providing:
- Investment Networks: Connecting local startups with global venture capital via global healthcare innovation funds and open innovation programs.
- Market Access: Facilitating entry into markets in the U.S. and Europe.
- Regulatory Flexibility: Encouraging a shift toward “open-minded” reviews of new technologies, such as digital twins, to reduce the time and cost of clinical trials.
Industry experts clarify that the goal of medical AI is not to replace physicians but to optimize their efficiency. Kim Kyung-hoon of OpenAI Korea explained that AI is currently expanding beyond simple document drafting into the realm of R&D and research data analysis. He noted that for AI to be effective in a clinical setting, it requires more than just model performance; it needs systematic data management, strict security governance, and sufficient contextual data to support medical decision-making.
| Current Strength | Commercial Barrier | Proposed Solution |
|---|---|---|
| Medical data & infrastructure | Ambiguous payment/reimbursement models | Quantifiable evidence of cost-saving & clinical value |
| Rapid AI adoption in R&D | Outdated government procurement (SI) style | Policy shift toward “ecosystem” and rule-setting |
| Strong startup ecosystem | Limited access to global markets | Open innovation partnerships with global pharma |
The consensus from the MSD Innovation Summit suggests that South Korea’s path to global leadership in medical AI depends less on further technical refinement and more on the creation of a sustainable economic framework. Success will require a synchronized effort between the government, medical institutions, and global partners to turn clinical potential into commercial reality.
Keep reading